Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8001 to 8050 of 8897 results

  1. Epilepsy in children and young people (QS27)

    This quality standard has been updated and replaced by NICE quality standard 211. 

    Withdrawn quality standard

  2. Venous thromboembolism in adults: diagnosis and management (QS29)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Withdrawn quality standard

  3. Venous thromboembolism in adults: reducing the risk in hospital (QS3)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Withdrawn quality standard

  4. Dementia: independence and wellbeing (QS30)

    This quality standard has been updated and replaced by NICE quality standard 184. 

    Withdrawn quality standard

  5. Diabetes in adults (QS6)

    This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).

    Withdrawn quality standard

  6. Obesity: clinical assessment and management (QS127)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Withdrawn quality standard

  7. Smoking: supporting people to stop (QS43)

    This quality standard has been updated and replaced by NICE quality standard 207.

    Withdrawn quality standard

  8. Glaucoma in adults (QS7)

    This quality standard has been updated and replaced by NICE quality standard 180.

    Withdrawn quality standard

  9. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ulcerative colitis: management (CG166)

    This guidance has been updated and replaced by NICE guideline NG130.

    Withdrawn guideline

  11. Myocardial infarction with ST-segment elevation: acute management (CG167)

    This guideline has been updated and replaced by NICE guideline NG185.

    Withdrawn guideline

  12. Acute kidney injury: prevention, detection and management (CG169)

    This guidance has been updated and replaced by NICE guideline NG148.

    Withdrawn guideline

  13. Dyspepsia: Management of dyspepsia in adults in primary care (CG17)

    This guidance has been updated and replaced by NICE guideline CG184.

    Withdrawn guideline

  14. Urinary incontinence in women: management (CG171)

    This guideline has been updated and replaced by NICE guideline NG123.

    Withdrawn guideline

  15. Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease (CG172)

    This guideline has been updated and replaced by NICE guideline NG185.

    Withdrawn guideline

  16. Prostate cancer: diagnosis and management (CG175)

    This guideline has been updated and replaced by NICE guideline NG131.

    Withdrawn guideline

  17. Head injury: assessment and early management (CG176)

    This guideline has been updated and replaced by the NICE guideline on head injury: assessment and management (NG232).

    Withdrawn guideline

  18. Osteoarthritis: care and management (CG177)

    This guidance has been updated and replaced by NICE guideline NG226.

    Withdrawn guideline

  19. Hypertension (CG18)

    This guidance has been updated and replaced by NICE guideline CG34.

    Withdrawn guideline

  20. Atrial fibrillation: management (CG180)

    This guidance has been updated and replaced by NICE guideline NG196.

    Withdrawn guideline

  21. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)

    This guideline has been updated and replaced by NICE guideline NG238.

    Withdrawn guideline

  22. Chronic kidney disease in adults: assessment and management (CG182)

    This guidance has been updated and replaced by NICE guideline NG203.

    Withdrawn guideline

  23. Multiple sclerosis in adults: management (CG186)

    This guidance has been updated and replaced by NICE guideline NG220.

    Withdrawn guideline

  24. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

    Technology appraisal guidance
    In development

  25. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    In development Reference number: GID-TA11491 Expected publication date: TBC

    Technology appraisal guidance
    In development

  26. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    In development Reference number: GID-TA11511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  27. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    In development Reference number: GID-TA11406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development

  29. Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife (IPG85)

    Interventional procedures, IPG85 - Issued: August 2004 --> This guidance has been updated and replaced by NICE HealthTech guidance 608. 

    Withdrawn guidance

  30. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    Discontinued Reference number: GID-TA11712

    Technology appraisal guidance
    Discontinued

  31. Baloxavir marboxil for treating and preventing influenza in people 3 weeks to 11 years [ID6554]

    In development Reference number: GID-TA11732 Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Intramedullary distraction for lower limb lengthening (IPG197)

    This guidance has been updated and replaced by NICE HealthTech guidance 613.

    Withdrawn guidance

  33. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  34. Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)

    In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008

    Withdrawn guidance

  35. Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA12)

    This guidance has been replaced by NICE technology appraisal guidance 47. 

    Withdrawn guidance

  36. Cardiac resynchronisation therapy for the treatment of heart failure (TA120)

    This guidance has been updated and replaced by NICE technology appraisal guidance 314.

    Withdrawn guidance

  37. Alteplase for the treatment of acute ischaemic stroke (TA122)

    This guidance has been updated and replaced by NICE technology appraisal guidance 264 issued in September 2012.

    Withdrawn guidance

  38. Infliximab for subacute manifestations of ulcerative colitis (TA140)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Withdrawn guidance

  39. Abatacept for the treatment of rheumatoid arthritis (TA141)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 195.

    Withdrawn guidance

  40. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)

    This guidance has been replaced by NICE technology appraisal guidance 323.

    Withdrawn guidance

  41. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Withdrawn guidance

  42. Rimonabant for the treatment of overweight and obese adults (TA144)

    This appraisal has been withdrawn. This is because the marketing authorisation for rimonabant was withdrawn on 16 January 2009.

    Withdrawn guidance

  43. Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)

    This appraisal has been updated and replaced by NICE technology appraisal 214.

    Withdrawn guidance

  44. Zanamivir for the treatment of influenza in adults (TA15)

    This guidance has been replaced by NICE technology appraisal guidance 58 [Replaced by NICE technology appraisal guidance 168].

    Withdrawn guidance

  45. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  46. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  47. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (TA132)

    This guidance has been updated and replaced by NICE technology appraisal guidance 385.

    Withdrawn guidance

  48. Omalizumab for severe persistent allergic asthma (TA133)

    This guidance has been replaced by NICE technology appraisal guidance 278.

    Withdrawn guidance

  49. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  50. The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C (TA14)

    This guidance has been replaced by NICE technology appraisal guidance 75.

    Withdrawn guidance